Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Lee Newman and Lisa Maier.

 
Connection Strength
 
 
 
2.639
 
  1. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med. 2005 Jan 01; 171(1):54-60.
    View in: PubMed
    Score: 0.303
  2. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, Du Bois R, Silveira L, Fontenot AP, Sawyer RT, Wilcox E, Newman LS. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease. J Immunol. 2003 Dec 15; 171(12):6910-8.
    View in: PubMed
    Score: 0.288
  3. Maier LA, Kittle LA, Mroz MM, Newman LS. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease. Am J Ind Med. 2003 Jun; 43(6):592-601.
    View in: PubMed
    Score: 0.277
  4. Maier L, Martyny J, Mroz M, McGrath D, Lympany P, duBois R, Zhang L, Murphy J, Newman LS. Genetic and environmental risk factors in beryllium sensitization and chronic beryllium disease. Chest. 2002 Mar; 121(3 Suppl):81S.
    View in: PubMed
    Score: 0.254
  5. Smith DE, Golden AP, Stange AW, Barker E, Mroz M, BarĂ³n AE, Ghosh D, Maier L, Cragle D, Newman LS. Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT). Am J Ind Med. 2018 07; 61(7):592-604.
    View in: PubMed
    Score: 0.193
  6. Maier LA, Barkes BQ, Mroz M, Rossman MD, Barnard J, Gillespie M, Martin A, Mack DG, Silveira L, Sawyer RT, Newman LS, Fontenot AP. Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease. Respir Med. 2012 Dec; 106(12):1810-3.
    View in: PubMed
    Score: 0.132
  7. Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Cragle DL, Tankersley WG, Wells SM, Newman LS, Maier LA. Exposure and genetics increase risk of beryllium sensitisation and chronic beryllium disease in the nuclear weapons industry. Occup Environ Med. 2011 Nov; 68(11):842-8.
    View in: PubMed
    Score: 0.119
  8. Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Fingerlin TE, Sato H, Newman LS, Maier LA. Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med. 2011 Jun 15; 183(12):1680-8.
    View in: PubMed
    Score: 0.119
  9. Tooker BC, Bowler RP, Orcutt JM, Maier LA, Christensen HM, Newman LS. SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease. Occup Environ Med. 2011 Oct; 68(10):759-64.
    View in: PubMed
    Score: 0.118
  10. Mroz MM, Maier LA, Strand M, Silviera L, Newman LS. Beryllium lymphocyte proliferation test surveillance identifies clinically significant beryllium disease. Am J Ind Med. 2009 Oct; 52(10):762-73.
    View in: PubMed
    Score: 0.108
  11. Sawyer RT, Fontenot AP, Barnes TA, Parsons CE, Tooker BC, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Hagman J, Newman LS. Beryllium-induced TNF-alpha production is transcription-dependent in chronic beryllium disease. Am J Respir Cell Mol Biol. 2007 Feb; 36(2):191-200.
    View in: PubMed
    Score: 0.087
  12. Newman LS, Maier LA, Martyny JW, Mroz MM, VanDyke M, Sackett HM. Beryllium workers' health risks. J Occup Environ Hyg. 2005 Jun; 2(6):D48-50.
    View in: PubMed
    Score: 0.080
  13. Sackett HM, Maier LA, Silveira LJ, Mroz MM, Ogden LG, Murphy JR, Newman LS. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J Occup Environ Med. 2004 Sep; 46(9):953-61.
    View in: PubMed
    Score: 0.076
  14. Sawyer RT, Day BJ, Fadok VA, Chiarappa-Zucca M, Maier LA, Fontenot AP, Silveira L, Newman LS. Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease. Am J Respir Cell Mol Biol. 2004 Oct; 31(4):470-7.
    View in: PubMed
    Score: 0.075
  15. Sawyer RT, Parsons CE, Fontenot AP, Maier LA, Gillespie MM, Gottschall EB, Silveira L, Newman LS. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP. Am J Respir Cell Mol Biol. 2004 Jul; 31(1):122-30.
    View in: PubMed
    Score: 0.073
  16. Kittle LA, Sawyer RT, Fadok VA, Maier LA, Newman LS. Beryllium induces apoptosis in human lung macrophages. Sarcoidosis Vasc Diffuse Lung Dis. 2002 Jun; 19(2):101-13.
    View in: PubMed
    Score: 0.065
  17. Sawyer RT, Maier LA, Kittle LA, Newman LS. Chronic beryllium disease: a model interaction between innate and acquired immunity. Int Immunopharmacol. 2002 Feb; 2(2-3):249-61.
    View in: PubMed
    Score: 0.063
  18. Martin AK, Mack DG, Falta MT, Mroz MM, Newman LS, Maier LA, Fontenot AP. Beryllium-specific CD4+ T cells in blood as a biomarker of disease progression. J Allergy Clin Immunol. 2011 Nov; 128(5):1100-6.e1-5.
    View in: PubMed
    Score: 0.031
  19. Sato H, Woodhead FA, Ahmad T, Grutters JC, Spagnolo P, van den Bosch JM, Maier LA, Newman LS, Nagai S, Izumi T, Wells AU, du Bois RM, Welsh KI. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum Mol Genet. 2010 Oct 15; 19(20):4100-11.
    View in: PubMed
    Score: 0.028
  20. Dobis DR, Sawyer RT, Gillespie MM, Newman LS, Maier LA, Day BJ. Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production. Am J Respir Cell Mol Biol. 2010 Oct; 43(4):458-64.
    View in: PubMed
    Score: 0.027
  21. Dobis DR, Sawyer RT, Gillespie MM, Huang J, Newman LS, Maier LA, Day BJ. Modulation of lymphocyte proliferation by antioxidants in chronic beryllium disease. Am J Respir Crit Care Med. 2008 May 01; 177(9):1002-11.
    View in: PubMed
    Score: 0.024
  22. Jonth AC, Silveira L, Fingerlin TE, Sato H, Luby JC, Welsh KI, Rose CS, Newman LS, du Bois RM, Maier LA. TGF-beta 1 variants in chronic beryllium disease and sarcoidosis. J Immunol. 2007 Sep 15; 179(6):4255-62.
    View in: PubMed
    Score: 0.023
  23. Fontenot AP, Palmer BE, Sullivan AK, Joslin FG, Wilson CC, Maier LA, Newman LS, Kotzin BL. Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response. J Clin Invest. 2005 Oct; 115(10):2886-93.
    View in: PubMed
    Score: 0.020
  24. Pott GB, Palmer BE, Sullivan AK, Silviera L, Maier LA, Newman LS, Kotzin BL, Fontenot AP. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol. 2005 May; 115(5):1036-42.
    View in: PubMed
    Score: 0.020
  25. Sawyer RT, Dobis DR, Goldstein M, Velsor L, Maier LA, Fontenot AP, Silveira L, Newman LS, Day BJ. Beryllium-stimulated reactive oxygen species and macrophage apoptosis. Free Radic Biol Med. 2005 Apr 01; 38(7):928-37.
    View in: PubMed
    Score: 0.020
  26. Fontenot AP, Maier LA, Canavera SJ, Hendry-Hofer TB, Boguniewicz M, Barker EA, Newman LS, Kotzin BL. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J Immunol. 2002 Apr 01; 168(7):3627-34.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)